Results 151 to 160 of about 8,509,826 (346)
Editorial: Placebo Effect in Pain and Pain Treatment
Frontiers in Pain Research, 2022 Michael H. Bernstein +2 more
doaj +1 more source
Annals of Gastroenterological Surgery, EarlyView.In an analysis of two RCTs of IRI‐based second‐line chemotherapy for AGC, patients with prior gastrectomy had better OS and PFS than patients without prior gastrectomy. Furthermore, patients with prior gastrectomy had a better prognosis in OS and PFS adjusted for background factors as well. Abstract Aims Second‐line chemotherapy (SLC) improves survival
Kazuhiro Nishikawa +12 more
wiley +1 more source
Annals of Gastroenterological Surgery, EarlyView.Abstract We reviewed the current status and perspectives on salvage esophagectomy for initially unresectable locally advanced esophageal squamous cell carcinoma (ESCC) in the era of minimally invasive surgery and immunotherapy. Although the standard treatment for these patients is definitive chemoradiotherapy (CRT), the complete response rate to CRT ...
Hiroshi Saeki +4 more
wiley +1 more source
Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer
Cancer Medicine, Volume 11, Issue 24, Page 5001-5012, December 2022., 2022 Nerve invasion (N‐inv) is an important prognostic factor in pancreatic ductal adenocarcinoma (PDAC). To elucidate circulating stimulators for nerve invasion, the authors evaluated the stimulant activity and the inhibitory effects of IL‐6/gp130 axis. Biological activity of IL‐6/gp130 axis promoted nerve invasion in murine model and was upregulated in ...
Hidetaka Suzuki +9 more
wiley +1 more source
Mediators of Placebo Response to Cannabinoid Treatment in Children with Autism Spectrum Disorder. [PDF]
J Clin Med, 2023 Aran A +4 more
europepmc +1 more source
Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo [PDF]
, 1998 S O Langley +3 more
openalex +1 more source
TP53‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, EarlyView.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source
A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. [PDF]
Clin Transl Sci, 2023 Moein A +5 more
europepmc +1 more source
Placebo response in schizophrenia
European Psychiatry, 1994 SummaryA review of the literature on placebo-controlled studies in schizophrenia reveals, that the percentage of placebo responders in short-term trials amounts to 0–40%; on active treatment the response rate is 40–60%. In relapse prevention studies 18–100% of patients on placebo relapsed as compared to 0–40% on active treatment.
openaire +2 more sources
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
American Journal of Hematology, EarlyView.ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +1 more source